377.5% Abu Dhabi screening rise puts breast cancer follow-up in focus

UAE breast cancer survivors profiled by Gulf News have turned October awareness into an operational question for providers: can clinics, insurers and employers support women after diagnosis, treatment and discharge?

The highest-stakes readers are COOs, medical directors and insurers. The immediate issue is follow-up capacity in Dubai, where the Dubai Health Authority (DHA) regulates providers, then Abu Dhabi and Al Ain under the Department of Health Abu Dhabi (DOH), and the northern emirates under the Ministry of Health and Prevention (MOHAP).

What the Gulf News story adds

The Gulf News article centres on women living in the UAE who describe breast cancer as a medical event and a long recovery process. Maria Sirotinina, a MedTech leader and biomedical engineer, said she was 36 when a full-body check-up and ultrasound found a suspicious mass in June 2022. A biopsy confirmed breast cancer.

That age matters for clinics. Standard population screening targets women aged 40 and older, but symptomatic patients, high-risk patients and women with suspicious imaging need a diagnostic route at any age. Intake teams should separate screening mammograms from diagnostic mammograms, breast ultrasound, biopsy referral and oncology navigation.

“Emotional recovery often lags behind physical recovery.” Hiba Salem, Psycho-Oncology & Palliative Psychology Specialist at Sage Clinic, told Gulf News.

For operators, that sentence has a service-design consequence. Survivorship care needs more than surgical oncology and chemotherapy slots. It needs psycho-oncology referral, lymphoedema screening, fertility counselling when relevant, return-to-work documentation and medication adherence checks.

Screening rules and payer checks

DHA’s Dubai Periodic Health Screening Guideline, issued on 11 March 2024 and effective from 11 May 2024, says women aged 40 and older are advised to have a mammogram every two years. It also states that screening may start earlier when there is family history or a known inherited genetic mutation.

DOH’s breast cancer screening standard for Abu Dhabi sets higher-intensity pathways for increased-risk women. It lists annual mammography and annual MRI for women aged 25 and older with strong family history or genetic predisposition, and clinical breast examination every six to 12 months for several increased-risk groups.

Abu Dhabi has evidence that outreach changes demand. The Abu Dhabi Public Health Centre (ADPHC) said on 5 October 2026 that breast cancer screenings rose 377.5% in October 2025 compared with October 2024 during its “Check What Really Matters” campaign.

• Dubai clinics should check DHA screening guidance and insurer pre-authorisation rules before advertising October packages.
• Abu Dhabi providers should verify DOH risk-category documentation, especially MRI, genetic counselling and annual follow-up claims.
• Northern emirates providers should map MOHAP guidance to their insurer networks and referral hospitals.
• Patients should ask whether a quote covers consultation, mammogram, ultrasound, radiologist report and follow-up visit.

For self-pay patients, published UAE provider prices show broad variation. Mediclinic lists a mammogram and breast ultrasound package at AED 725. Other Dubai clinics advertise screening packages around AED 450 to AED 599. Those figures should be treated as package prices, not universal tariffs, because biopsy, MRI, pathology and oncology consultation may be billed separately.

Why clinics and insurers should act now

The commercial implication is clear. Breast cancer demand is moving upstream into screening and downstream into survivorship. Clinics that stop at the scan risk losing patients to centres that coordinate imaging, biopsy, oncology referral, mental health support and insurance paperwork in one pathway.

Insurers have a parallel exposure. Daman guidance says screening mammography coverage depends on plan benefits and designated network providers. The Thiqa programme, managed by Daman, covers eligible UAE nationals and those of similar status in Abu Dhabi. Patients with Sukoon or other private plans should check network status, annual screening benefits and pre-approval requirements before booking.

Employers also have a practical role. HR teams can reduce late presentation by offering paid time for screening, publishing insurer network links and naming one benefits contact for oncology claims. Medical directors should audit whether abnormal mammograms have a documented follow-up call within a defined number of working days.

The next test for UAE providers is continuity. October campaigns can bring women into screening. The harder work is making sure abnormal findings move quickly into diagnosis, and that survivors have a visible route back to care when treatment ends. Patients and operators can start by using the UAE Open Healthcare Directory to find licensed oncology providers across Dubai, Abu Dhabi, Al Ain and the northern emirates.